Nonsteroidal antiinflammatory drugs: Past, present and future

Pharmacological Research

Volumn 59, Issue 5, 2009, Pages 285-289

  Patrono, Carlo ^a   Rocca, Bianca ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Aspirin; Coxib; Cyclooxygenases; EP antagonists; NSAIDs; PGE synthases

Indexed keywords

2 [6 CHLORO 1H PHENANTHRO[9,10 D]IMIDAZOL 2 YL]ISOPHTHALONITRILE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; MF 498; MF 63; N [[4 (5,9 DIETHOXY 6 OXO 6,8 DIHYDRO 7H PYRROLO[3,4 G]QUINOLIN 7 YL) 3 METHYLBENZYL]SULFONYL] 2 (2 METHOXYPHENYL)ACETAMIDE; NAPROXCINOD; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARACHIDONIC ACID METABOLISM; CANCER PREVENTION; CARDIOTOXICITY; CARDIOVASCULAR RISK; COLORECTAL ADENOMA; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL GUINEA PIG; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL MUCOSA; HEART PROTECTION; HUMAN; HYPERPYREXIA; IC 50; INFLAMMATION; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; OSTEOARTHRITIS; PAIN; PRESCRIPTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT CONTRAINDICATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RISK ASSESSMENT;

EID: 63649148593     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.01.011     Document Type: Review

References (35)

1. Burke A., Smyth E., and FitzGerald G.A. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Brunton L.L. (Ed). Goodman & Gilman's the pharmacological basis of therapeutics, (2006), McGraw-Hill, New York, NY, USA 673-715
2. Patrono C., García Rodríguez L.A., Landolfi R., and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
3. García Rodríguez L.A., and Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132 (2007) 498-506
4. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
5. García Rodríguez L.A., Varas C., and Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 11 (2000) 382-387
6. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
7. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
8. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-675
9. Majerus P.W. Arachidonate metabolism in vascular disorders. J Clin Invest 72 (1983) 1521-1525
10. Topper J.N., Cai J., Falb D., and Gimbrone Jr. M.A. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93 (1996) 10417-10422
11. Cullen L., Kelly L., Connor S.O., and Fitzgerald D.J. Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther 287 (1998) 578-582
12. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., and FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96 (1999) 272-277
13. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
14. Patrono C, Baigent C. Cardiovascular effects of low-dose aspirin, traditional nonsteroidal antiinflammatory drugs and coxibs. Mol Interv; in press.
15. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
16. Capone M.L., Tacconelli S., Sciulli M.G., Grana M., Ricciotti E., Minuz P., et al. Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109 (2004) 1468-1477
17. Capone M.L., Tacconelli S., Sciulli M.G., Anzellotti P., Di Francesco L., Merciaro G., et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 322 (2007) 453-460
18. Cannon C.P., Curtis S.P., FitzGerald G.A., Krum H., Kaur A., Bolognese J.A., et al. For the MEDAL Steering Committee, cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368 (2006) 1771-1781
19. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet 370 (2007) 2138-2151
20. Antman E.M., Bennett J.S., Daugherty A., Furberg C., Roberts H., and Taubert K.A. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 (2007) 1634-1642
21. American College of Rheumatology ad hoc group on use of selective and nonselective nonsteroidal antiinflammatory drugs. Recommendations for use of selective and nonselective nonsteroidal anti-inflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008;59: 1058-73.
22. Chan F.K., Abraham N.S., Scheiman J.M., and Laine L. First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 103 (2008) 2908-2918
23. Alacqua M., Trifirò G., Cavagna L., Caporali R., Montecucco C.M., Moretti S., et al. Prescribing pattern of drugs in the treatment of osteoarthritis in italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum 59 (2008) 568-574
24. Teeling M., O'Connor H., Feely J., and Bennet K. What therapies have replaced rofecoxib in Ireland?. Br J Clin Pharmacol 64 (2007) 536-541
25. García Rodríguez L.A., Tacconelli S., and Patrignani P. Role of dose-potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52 (2008) 1628-1636
26. Baron J.A., Sandler R.S., Bresalier R.S., Lanas A., Morton D.G., Riddell R., et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372 (2008) 1756-1764
27. Solomon S.D., Wittes J., Finn P.V., Fowler R., Viner J., Bertagnolli M.M., et al. For the Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117 (2008) 2104-2113
28. Wallace JL, Viappiani S, Bolla M. Cyclooxygenase-inhibiting nitric oxide donators (CINODs) for osteoarthritis. TiPS; in press.
29. Samuelsson B., Morgenstern R., and Jakobsson P.-J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59 (2007) 207-224
30. Xu D., Rowland S.E., Clark P., Giroux A., Côté B., Guiral S., et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 326 (2008) 754-763
31. Wang M., Zukas A.M., Hui Y., Ricciotti E., Puré E., and FitzGerald G.A. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 103 (2006) 14507-14512
32. Degousee N., Fazel S., Angoulvant D., Stefanski E., Pawelzik S.C., Korotkova M., et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 117 (2008) 1701-1710
33. Nakao K., Murase A., Ohshiro H., Okumura T., Taniguchi K., Murata Y., et al. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322 (2007) 686-694
34. Clark P., Rowland S.E., Denis D., Mathieu M.C., Stocco R., Poirier H., et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3 -methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther 325 (2008) 425-434
35. Murase A., Okumura T., Sakakibara A., Tonai-Kachi H., Nakao K., and Takada J. Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation. Eur J Pharmacol 580 (2008) 116-121